Article

Addressing market access challenges as CGTs expand to larger patient populations

Cell and gene therapies (CGTs) represent a paradigm shift in the treatment of numerous complex diseases, offering potentially curative options that were once unimaginable. However, as these transformative therapies gain traction, the U.S. market faces a multitude of market access challenges that must be addressed to realize their full potential. For your commercialization strategy to succeed, you should consider the strategies in this article. 

Fill out the form below to read article

Connect with our cell and gene therapy team

Schedule some time with our cell and gene therapy experts today. We look forward to hearing from you.

Related resources

White paper

Project Orbis Drug Registration white paper

White paper

Mastering the complexities of targeted medicines

Webinar

How to turn poor TMF quality into TMF operational excellence

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.